心脏移植是目前临床治疗各类终末期心脏病的最有效手段。然而，如何有效提高离体供心的保存质量及保存期限，仍是心脏移植领域亟需解决的瓶颈问题。我们在前期动物实验中发现：含氢保存液对离体心脏有保护作用，且移植后缺血再灌注损伤、间质水肿和心肌坏死并发症减少。然而，由于冷冻保存固有存在的冰晶损伤，离体保存期限未能显著延长。我们进一步采用含氢急速液体冷冻保存技术，发现含氢急速冷冻保存液显著减少离体心脏内冰晶，减轻相关的挤压损伤及冻融效应，显著延长离体心脏保存期限。然而，该方法是如何减轻心肌缺血再灌注损伤、延长心脏保存时间的？尚未明确，其分子机制仍需进一步探讨。本项目拟在前期研究基础上，通过建立动物异位心脏移植模型，采用基因组学及表观遗传学等方法研究与心脏保存相关的mRNA、miRNA的表达模式，阐明含氢急速冷冻保存液发挥心脏保护作用的分子机制，为临床转化应用提供科学依据。

Heart transplantation is the most effective method in the treatment of various end-stage heart disease. However, how to effectively improve the preservation quality and life of donor heart in vitro is still a bottleneck problem that need to be solved in the field of heart transplantation. In previous animal experiments, we found that hydrogen-containing preservation solution had protective effect on isolated heart. The complications of ischemia reperfusion injury, interstitial edema and myocardial necrosis after transplantation were reduced. However, we failed to significantly prolong the preservation life in vitro due to the damage caused by ice crystals inherent in cryopreservation. Hydrogen-containing rapid liquid cryopreservation technology was then adopted. And we found that hydrogen-containing rapid cryopreservation solution significantly reduced the ice crystals in the isolated heart, alleviated relevant crush injury and freeze-thaw effect, and significantly extended the preservation life of the isolated heart. However, the molecular mechanisms underlying the cardiacprotective effects of this method still awaits further exploration. On the basis of previous studies, this project intends to establish an animal heterotopic heart transplantation model, explore the expression patterns of mRNAs and miRNAs that related to heart preservation by genomics and epigenetics methods, and elucidate the molecular mechanisms underlying the cardiacprotective effects of hydrogen-containing cryopreservation solution, thus providing scientific basis for clinical transformation and application.